ABC News January 13, 2020

Insys Therapeutics executive sentenced to 3 years in prison for lying about opioid addiction

WATCH: Inside alleged scheme Insys Therapeutics used to sell deadly opioid: Part 1

A former executive of Insys Therapeutics was sentenced Monday to nearly three years in prison as part of the first federal case meant to hold an opioids manufacturer criminally accountable for the ongoing epidemic in the country.

Former Insys Vice President of Managed Markets Michael Gurry, whose sentence was handed down by a federal judge in Boston, received less than the 11 years prosecutors sought for someone they said instructed underlings to lie to insurance companies about patient diagnoses so the insurers would cover the company’s ts highly addictive under-the-tongue fentanyl spray, Subsys.

MORE: How authorities say drugmaker paid off doctors, lied to insurance companies to push potentially lethal fentanyl-based drug

Gurry, 56, will serve 33 months in prison, three years of supervised release and forfeit $3.6 million. He was convicted of racketeering conspiracy in May 2019.

Six other former Insys executives, including founder John Kapoor, face sentencing in the coming days.

U.S. Attorney's Office for the Southern District of Alabama via Reuters, FILE
A box of the Fentanyl-based drug Subsys, made by Insys Therapeutics Inc, in an undated photograph provided by the U.S. Attorney's Office for the Southern District of Alabama.

"From May 2012 to December 2015, Gurry and his co-defendants conspired to bribe practitioners, many of whom operated pain clinics, in order to induce them to prescribe Insys’ fentanyl-based pain medication, Subsys, to patients, often when medically unnecessary," the government said in a press release announcing Gurry's sentencing.

Kapoor, Gurry and the others were charged with paying millions of dollars in bribes to doctors nationwide so they would over-prescribe Subsys.

MORE: Opioid maker Insys to be delisted from NASDAQ following bankruptcy filing

Prosecutors have asked that Kapoor be put away for 15 years. The defense said he deserved no more than one year since he developed Subsys after watching his wife suffer and die from breast cancer.

At least two other drug distribution companies face criminal charges related to the opioids crisis but Insys is the first, and so far only, manufacturer.

Steven Senne/AP, File
In this Jan. 30, 2019, file photo, Insys Therapeutics founder John Kapoor leaves federal court in Boston.

The company filed for Chapter 11 bankruptcy in June 2019, one week after it agreed to pay $225 million to settle the federal government's criminal and civil investigations into the company's illegal marketing scheme of Subsys.

Insys was de-listed from the Nasdaq following the bankruptcy filing.

About 130 Americans die every day on average from an opioid overdose, according to the Centers for Disease Control.

ABC News' Mark Osborne contributed to this report.